Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results

Acumen Pharmaceuticals, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/18/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/17/2023 144 Form 144 - Report of proposed sale of securities:
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Investor presentation, Quarterly results
Docs: "Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights",
"Corporate Presentation August 2023 1 Forward-Looking Statements 2 This"
07/25/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
07/25/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/20/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/20/2023 8-K Quarterly results
07/17/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/17/2023 8-K Results of Operations and Financial Condition  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
07/17/2023 8-K Quarterly results
06/08/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "ACUMEN PHARMACEUTICALS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION"
06/07/2023 4 Stalfort John A III (Director) has filed a Form 4 on Acumen Pharmaceuticals, Inc.
Txns: Granted 25,000 options to buy @ $5.2, valued at $130k
06/07/2023 4 Stoppel Laura (Director) has filed a Form 4 on Acumen Pharmaceuticals, Inc.
Txns: Granted 25,000 options to buy @ $5.2, valued at $130k
06/07/2023 4 Porter Derrell (Director) has filed a Form 4 on Acumen Pharmaceuticals, Inc.
Txns: Granted 25,000 options to buy @ $5.2, valued at $130k
06/07/2023 4 Ives Jeffrey L. (Director) has filed a Form 4 on Acumen Pharmaceuticals, Inc.
Txns: Granted 25,000 options to buy @ $5.2, valued at $130k
06/07/2023 4 Fountain Nathan B (Director) has filed a Form 4 on Acumen Pharmaceuticals, Inc.
Txns: Granted 25,000 options to buy @ $5.2, valued at $130k
06/07/2023 4 Drapkin Kimberlee C (Director) has filed a Form 4 on Acumen Pharmaceuticals, Inc.
Txns: Granted 25,000 options to buy @ $5.2, valued at $130k
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Investor presentation, Quarterly results
Docs: "Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Highlights",
"Corporate Presentation May 2023 1 Forward-Looking Statements 2 This"
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/27/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
04/27/2023 8-K Quarterly results
04/14/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/28/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/27/2023 10-K Annual Report for the period ended December 31, 2022
03/27/2023 8-K Investor presentation
Docs: "Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights",
"Corporate Presentation March 2023 1 Forward-Looking Statements 2 This"
03/15/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "AMENDED AND RESTATED BYLAWS OF"
02/14/2023 SC 13G/A Sands Capital Ventures, LLC reports a 8.3% stake in Acumen Pharmaceuticals, Inc.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/01/2023 8-K Quarterly results
01/18/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/18/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy